CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it has granted equity inducement awards to 11 new ...

Highlights,Madrigal Pharmaceuticals shows strong share movement in recent weeks,Revenue growth remains uneven across short- ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced that the European Commission (EC) has granted conditional ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...

Madrigal Pharmaceuticals MDGL announced that the European Commission (EC) has granted a conditional marketing authorization ...

The European Commission (EC) has granted conditional marketing authorization for Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic ...

In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

Lebowitz covers the Healthcare sector, focusing on stocks such as Incyte, Schrodinger, and Madrigal Pharmaceuticals. Viking Therapeutics has an analyst consensus of Strong Buy, with a price target ...

Rezdiffra is the first and only medication approved for people living with MASH in the European Union <li /> Conditional marketing au ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.